The two actions will help the firm further develop and manufacture solid oral doses for biopharmaceutics classification system (BCS) III and IV compounds, it said.

The expanded facility is 32,000 sq ft, of which 6,000 sq ft is cleanroom space and 2,500 is for containment and processing of high-potency active pharmaceutical ingredients (APIs).

Porton Biologics establishes CGT CDMO services with $61.4M in financing
Porton Biologics, a subsidiary of cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) Porton Pharma Solutions, has...

Quotient Sciences acquires CDMO Arcinova
Quotient Sciences has purchased U.K. multiservice contract development and manufacturing organization (CDMO) Arcinova.

Eurofins CDMO expands drug product operations in Canada
Eurofins contract development and manufacturing organization (CDMO) has expanded its existing drug product operation capabilities with a new manufacturing...